HighTide Therapeutics, Inc.
君圣泰医药
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2511)

HIGHTIDE THERAPEUTICS' HTD1801 ACHIEVES GREATER HBA1C REDUCTION AND SUPERIOR CARDIOMETABOLIC MARKER IMPROVEMENT VERSUS DAPAGLIFLOZIN IN PHASE III HEAD-TO-HEAD TRIAL

This announcement is made by HighTide Therapeutics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Group.

The board of directors (the "**Board**") of the Company announces positive topline results from its Phase III HARMONY trial, demonstrating that HTD1801 achieved the primary endpoint of this trial, with superior improvements in key cardiometabolic markers in patients with type 2 diabetes mellitus (T2DM) compared to dapagliflozin.

These data reinforce HTD1801's potential to target the metabolic drivers of Type 2 diabetes mellitus progression while delivering cardiometabolic benefits

HARMONY (NCT06415773) is a randomized, double-blind, active-controlled, Phase III clinical trial evaluating the efficacy and safety of HTD1801 compared with dapagliflozin in adults with T2DM inadequately controlled with metformin (N=369). The primary endpoint assessed the change in HbA1c from baseline to Week 24 versus dapagliflozin, with a non-inferiority margin of 0.4%. Gated secondary endpoints included multiple cardiometabolic markers.

- **The Phase III head-to-head trial met its primary endpoint: HTD1801 achieved a –1.12% LS mean reduction in HbA1c at Week 24, compared with –0.93% for dapagliflozin (LS mean difference –0.20%; 95% CI –0.37 to –0.03; P < 0.001).**

- **HTD1801 met gated secondary endpoints, demonstrating superior improvements in LDL-C and non-HDL-C reduction with lower rate of statin intensification compared with dapagliflozin. HTD1801 also delivered superior improvements in other cardiometabolic markers, including a higher proportion of patients reaching HbA1c < 7.0%, greater reduction in Lp(a).**

- **The safety and tolerability profile of HTD1801 was favorable, with serious adverse events reported in 3.8% of patients versus 4.4% for dapagliflozin; the most common side-effects were mild to moderate gastrointestinal events, and no severe hypoglycemia occurred in the HTD1801 arm.**

Collectively, these results indicate that HTD1801 may offer broader clinical benefits than SGLT2 inhibitor, targeting the underlying metabolic and inflammatory drivers of T2DM. The HARMONY study is the third consecutive successful Phase III trial of HTD1801, following SYMPHONY-1 and SYMPHONY-2, underscoring its strong potential as a foundational therapy in cardiovascular-kidney-metabolic (CKM) disease management. HighTide Therapeutics plans to submit a New Drug Application (NDA) for HTD1801 later this year.

ABOUT HTD1801

HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular-kidney-metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management.

ABOUT HIGHTIDE THERAPEUTICS, INC.

HighTide Therapeutics, Inc. (2511.HK) is a biopharmaceutical company dedicated to developing multifunctional, multi-targeted therapies for chronic metabolic diseases, with a strategic emphasis to address the residual risks of cardiovascular-kidney-metabolic (CKM) syndrome. The company focuses on delivering breakthrough treatments that generate comprehensive, multi-organ benefits for patients worldwide. HighTide has built an innovative, globally integrated pipeline of proprietary assets and advanced multiple clinical programs across chronic metabolic diseases. The company's lead asset, HTD1801, has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration (FDA), and has been selected for China's *National Major Science and Technology Project for Significant New Drug Development*.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that HTD1801 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping
Executive Director and Chief Executive Officer

Hong Kong, December 02, 2025

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Mr. TAN Bo, Dr. LI Jin and Mr. HUNG Tak Wai as independent non-executive Directors.